Biocon’s Insulin Glargine Receives Regulatory Approval in Japan
  • Sat, 28-May-2016
  • Posted by: Biocon Biologics
No Comments

Biocon Q4FY16 Net Profit at Rs 361 Cr Revenue Crosses Rs 1,000 Cr; Up 17% FY 16 Revenues up 14% at Rs 3,570 Cr Net Profit at Rs 896 Cr
  • Tue, 26-Apr-2016
  • Posted by: Biocon Biologics
No Comments

Biocon Inks Co-Development & Commercialization Agreement with Lab PiSA for rh- Insulin in USA
  • Thu, 17-Mar-2016
  • Posted by: Biocon Biologics
No Comments

Biocon Gets its First Generic Formulation Approval in EU; On Track to Launch Rosuvastatin Tablets in FY 17
  • Mon, 15-Feb-2016
  • Posted by: Biocon Biologics
No Comments

Biocon Q3FY16 Net Profit Up 13% at Rs 103 Crore, EBITDA Increases 23% to Rs 209 Crore, Revenues at Rs 857 Crore, up by 10%
  • Thu, 21-Jan-2016
  • Posted by: Biocon Biologics
No Comments

Biocon Announces Data from Key Studies for Insulin Tregopil
  • Thu, 21-Jan-2016
  • Posted by: Biocon Biologics
No Comments
Report adverse event/ side effects and/or product complaints for Biocon Biologics products.

* Safe Harbour | Privacy Policy | Terms of Use © 2023, Biocon Biologics Limited (a Subsidiary of Biocon Limited). All Rights Reserved
Share